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Introduction		
	This	thesis	serves	to	explain	what	a	uterine	transplant	(UTx)	is	and	how	may	fit	into	society	and	pre-existing	medical	systems.		Uterine	transplantation	(the	act	of	surgically	transplanting	a	donor	uterus	into	a	person	who	lacks	one)	is	currently	in	the	clinical	trial	stage	in	several	countries	around	the	world	and,	as	with	any	new	medical	technology,	it	is	important	to	pinpoint	and	examine	the	bioethical	complexities	associated	with	the	procedure.		Before	uterine	transplants	become	more	accessible,	it	is	necessary	to	determine	who	will	be	helped	by	this	procedure	and	to	ensure	that	UTx	offers	more	benefits	than	risks.		This	thesis	will	strive	to	assess	the	ethicality	of	this	medical	innovation,	as	well	as	the	societal	motivations	that	have	led	to	its	development.		I	will	also	investigate	how	the	implementation	of	uterine	transplantation	in	the	medical	sphere	will	change	and	expand	in	the	future.			In	Chapter	1,	I	intend	to	briefly	outline	the	history	of	this	procedure	and	the	groups	that	could	benefit	from	this	burgeoning	technology.		This	chapter	will	also	include	a	brief	description	of	how	the	procedure	works,	and	an	outline	of	the	steps	leading	up	to	the	human	clinical	trial	stage.			When	discussing	any	new	medical	procedure	it	is	necessary	to	examine	its	bioethical	implications	and	to	perform	risk-benefit	analyses.		Chapter	2	will	largely	be	dedicated	to	this	task.		This	chapter	will	also	discuss	the	other	Assisted	Reproductive	Technologies	(ARTs)	that	are	currently	available	to	help	intended	parents	conceive.		Here	I	will	place	UTx	in	conversation	with	traditional	IVF	as	well	as	gestational	surrogacy.			
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Chapter	3	will	take	on	the	important	task	of	identifying	pre-existing	procedures	and	technologies	(colloquially	termed	“quality-of-life	procedures”)	that	may	supply	context	and	create	precedents	for	this	type	of	medical	innovation.		Additionally,	through	the	scrutiny	of	the	varied	motivations	pushing	patients	toward	quality-of-life	procedures	I	wish	to	demonstrate	how	societal	pressures	inform	the	techniques	and	procedures	that	are	sought	out	by	patients	and	subsequently	approved	by	the	medical	community.		Once	these	other	issues	are	fully	fleshed	out,	Chapter	4	shall	explore	the	future	of	uterine	transplantation.		I	will	explore	how	UTx	may	be	aided	in	the	future	by	other	scientific	advancements,	like	3D	bioprinting.		Additionally,	I	will	discuss	how	uterine	transplants	might	one	day	become	available	to	patients	other	than	cis-women	(ie.	trans	women,	cis-men,	etc),	which	might	further	revolutionize	human	reproduction.			I	will	finish	this	thesis	by	reiterating	my	main	points	and	summarizing	my	conclusions.		By	critically	examining	the	bioethical	risks	of	uterine	transplantation	in	this	thesis	I	do	not	intend	to	discourage	the	progression	of	clinical	trials	and	research	into	the	UTx	procedure.		Instead,	I	simply	aim	to	raise	awareness	of	all	ethical	considerations	associated	with	uterine	transplantation,	and	contemplate	a	future	involving	UTx.		 				
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Chapter	1	Uterine	Transplants:	Past	and	Present	Applications		 In	Germany,	in	1931,	the	transgender	woman	Lili	Elbe	became	the	world’s	first	uterine	transplant	recipient.		Three	months	later,	Elbe	died	from	paralysis	of	the	heart	due	to	organ	rejection.		Though	interest	in	uterine	transplants	persisted,	and	studies	were	conducted	to	discover	anti-rejection	medications	that	would	one	day	make	these	transplants	possible,	it	was	a	long	time	(almost	70	years)	before	another	patient	underwent	the	procedure	that	ultimately	ended	Elbe’s	life.		Today,	85	years	after	her	death,	uterine	transplants	are	finally	gaining	mainstream	attention	from	the	medical	and	scientific	fields,	but	many	members	of	the	general	public	still	have	no	idea	what	they	are	or	what	they	could	mean	for	societal	and	medical	advancement.		According	to	the	Hastings	Center,	a	preeminent	bioethics	research	institute,	a	uterine	transplant	is	an	experimental	procedure	developed	to	enable	women	without	uteri,	or	with	malformed	or	badly	damaged	uteri,	to	become	pregnant.		This	operation	involves	transplanting	a	uterus	from	a	living	or	deceased	donor	to	a	recipient	(Hastings	Center).		While	this	definition	is	limited,	due	to	its	gender-based	language	and	lack	of	procedural	descriptions,	it	does	offer	a	starting	point	for	understanding	uterine	transplantation	as	a	concept.		Generally,	‘women’	are	considered	to	be	individuals	with	internal	female	reproductive	organs	(a	vagina,	a	uterus,	Fallopian	tubes,	and	ovaries),	but	in	actuality	many	people	who	identify	as	women	are	born	without	one	or	all	of	these	organs.		The	current	research	on	uterine	transplants	focuses	on	female-bodied	individuals	(with	two	X-chromosomes)	who	
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were	either	born	without	uteri	or	who	have	had	their	uteri	removed	due	to	medical	complications.		Keeping	this	focus	in	mind,	for	the	majority	of	this	thesis	I	will	refer	to	people	with	uteri,	and	individuals	desiring	uterine	transplants,	as	“women”	and	use	the	pronouns	she,	her,	and	hers	to	address	them.		The	final	chapter	of	this	thesis	will	address	the	future	of	uterine	transplants,	and	it	is	there	that	I	will	take	the	time	to	discuss	the	potential	influence	of	uterine	transplants	in	the	trans	and	nonbinary	communities.			During	the	intervening	time	between	the	first	and	second	attempts	at	uterine	transplants,	medical	professionals	and	scientists	did	not	forget	about	fertility	issues,	but	instead	shifted	their	focus	to	other	assisted	reproductive	technologies	(ARTs).		It	was	throughout	this	time	that	In	Vitro	Fertilization	(IVF)	was	developed.		In	Vitro	Fertilization	is	a	process	where	mature	eggs	are	retrieved	(either	from	the	intended	mother’s	ovaries	or	from	a	donor’s	ovaries)	and	fertilized	by	sperm	in	a	laboratory	(Mayo	Clinic).	The	fertilized	eggs	(embryos)	are	then	implanted	into	the	uterus	of	a	gestational	carrier,	who	could	either	be	the	intended	mother	or	a	chosen	surrogate.		While	IVF	is	one	of	the	most	widespread	ARTs,	it	still	requires	a	functional	uterus,	and	therefore	does	not	eliminate	the	perceived	“need”	for	uterine	transplants.			Though	I	have	mentioned	a	shift	in	focus	from	UTx	to	IVF,	it	would	be	incorrect	to	claim	that	research	into	uterine	transplantation	entirely	halted	during	this	time.		UTx	research	was	still	conducted	in	certain	laboratories,	but	the	subjects	were	not	human.				During	the	time	before	modern	research	into	uterine	transplants	reached	the	stage	of	human	clinical	trials,	many	different	animal	trials	were	conducted	throughout	the	world,	and	some	are	still	ongoing.		The	three	main	types	of	animals	
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that	have	been	involved	in	these	studies	are	rodents	(rats	and	mice), large	domestic	species	(sheep	and	pigs)	and,	most	recently,	nonhuman	primates,	including	baboons	and	macaques.		Rodent	studies	were	used	to	develop	the	basic	procedure	for	uterine	transplants	that	was	adopted	and	greatly	altered	for	use	in	sheep	and	pig	studies.		These	animal	models	were	very	important	for	identifying	the	different	potentially	harmful	events	that	could	cause	transplants	to	be	unsuccessful,	and	analyzing	each	event	separately.		These	events	include	surgery	at	organ	recovery,	ischemia-reperfusion	damage,	surgery	at	transplantation,	rejection,	and	effects	of	immunosuppressive	medication.		By	isolating	each	event	through	the	use	of	control	groups,	researchers	were	able	to	determine	how	to	best	mitigate	these	dangers.			An	important	contribution	from	animal	trials	to	UTx	is	the	enhanced	knowledge	about	antirejection	drugs	that	have	made	allogeneic	transplants	and	transplants	from	dead	donors	possible	(Brännström	1270-71).		Rodent	trials	tested	the	efficacy	of	Cyclosporine	as	immunotherapy	against	allograft	rejection,	and	found	that	while	the	drug	was	able	to	partially	suppress	rejection	of	the	transplanted	uterus,	it	did	not	reduce	the	morphological	and	histological	signs	of	graft	rejection	enough	to	allow	for	long-term	graft	survival	(Wranning	378).		Later	trials	in	rats	showed	that	tacrolimus	monotherapy	is	capable	of	suppressing	rejection	of	an	allotransplanted	uterus	(Akhi	682).		These	trials	helped	to	determine	the	medical	regimen	for	human	subjects.				Now	that	this	research	has	moved	into	the	realm	of	human	trials,	it	is	important	to	examine	the	composition	of	the	pool	of	potential	recipients.		1	in	4,500	newborn	females	are	born	with	Mayer-Rokitansky-Küster-Hauser	syndrome,	a	congenital	
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disorder	that	mainly	affects	the	reproductive	system	and	causes	the	vagina	and	uterus	to	be	underdeveloped	or	absent	(U.S	National	Library	of	Medicine).	Individuals	with	MRKH	make	up	a	sizeable	portion	of	uterine	transplant	candidates,	but	there	are	many	other	medical	conditions	that	lead	to	dysfunctional	uteri.		Two	common	acquired	etiologies	that	make	uteri	incapable	of	gestating	include	fibroids	and	intrauterine	adhesions.		Additionally,	many	women	are	forced	to	have	hysterectomies	due	to	uterine	cancer,	excessively	heavy	periods,	endometriosis	and	a	variety	of	other	medical	issues.		Absolute	uterine	factor	infertility	(UFI)	is	the	term	used	to	encompass	all	causes	of	female	infertility	that	stem	from	the	anatomical	or	physiological	inability	of	a	uterus	to	sustain	gestation	(Lefkowitz	et	al.	439).		It	is	estimated	that	throughout	the	world	uterine	factor	infertility	affects	3–5%	of	the	female	population.			The	likelihood	of	a	woman	being	deemed	“in	need”	of	a	uterine	transplant	correlates	with	the	severity	of	her	conditions.		Subjects	who	have	been	labeled	100%	infertile	are	more	likely	to	be	candidates	for	clinical	trials	than	those	who	only	have	a	decreased	level	of	fertility.		That	being	said,	women	in	any	of	these	categories	could,	in	the	very	near	future,	find	themselves	on	waiting	lists	for	transplanted	uteri.						It	is	important	to	note	that	while	some	of	the	aforementioned	medical	conditions	themselves	can	be	life	threatening,	the	absence	of	a	functional	uterus,	or	any	uterus	at	all,	is	not	harmful	to	a	person’s	health.		Therefore,	the	motivations	for	research	into	uterine	transplants	and	the	desire,	held	by	some	women,	to	undergo	uterine	transplantation	come	from	a	realm	outside	of	the	preservation	of	life.		It	is	
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also	clear	that	the	sole	motivation	for	these	procedures	is	not	simply	to	allow	interested	parties	to	become	parents	because	other	avenues,	such	as	adoption	and	surrogacy,	are	available	to	fulfill	that	desire.		The	question	of	motivation	will	be	fleshed	out	more	thoroughly	in	later	chapters,	but	it	is	safe	to	say	that	those	individuals	who	are	seeking	out	uterine	transplants	are	doing	so	because	of	a	strong	desire	to	experience	pregnancy	and	give	birth	to	a	child.		Almost	seven	decades	after	the	first	uterine	transplant	was	performed,	on	April	6,	2000	doctors	in	Saudi	Arabia	performed	a	uterine	transplant	surgery,	transferring	a	healthy	uterus	from	a	46-year-old	living	donor	to	a	26-year-old	recipient	who	had	previously	undergone	a	hysterectomy.		The	doctors	who	conducted	this	transplant	were	aware	that	no	successful	human	uterine	transplant	had	ever	been	done,	and	with	that	in	mind	they	ran	an	animal	study.		The	study	involved	transplantation	in	16	female	baboons	and	2	female	goats,	and	produced	varied	results.	The	researchers	used	the	information	gained	from	the	animal	research	to	structure	their	human	“trial”	which	consisted	of	only	one	patient.		The	researchers	developed	their	own	surgical	techniques	and	immunosuppression	regimen	and	went	forward	with	what	they	considered	to	be	the	first	actual	human	uterine	transplant.		After	99	days	the	recipient	experienced	“a	sudden	feeling	of	heaviness,	with	a	foul-smelling	vaginal	discharge	on	straining”	(Fageeh	249-250)	and	after	diagnosing	the	patient	with	a	mechanical	occlusion	of	the	uterine	vessels	(which	resulted	in	a	uterine	infarction)	the	doctors	removed	the	transplant.		Though	the	donor	and	recipient	both	survived	the	surgeries,	practically	no	medical	professionals	consider	this	to	be	the	first	
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successful	uterus	transplant,	because	the	uterus	was	removed	before	completing	its	stated	purpose	of	gestating	a	fetus.				In	2011,	another	attempt	was	made	at	uterine	transplantation,	this	time	using	a	uterus	from	deceased	donor.		Doctors	in	Turkey	transplanted	the	uterus	of	a	22-year-old	brain-dead	woman	into	a	21-year-old	woman	with	congenital	uterovaginal	agenesis	(MRKH).		The	recipient	was	selected	out	of	a	group	of	10	candidates,	all	with	the	same	congenital	disorder,	due	to	her	age,	health,	and	the	fact	that	her	blood	type	matched	that	of	the	donor.		As	the	recipient	had	fully	functional	ovaries,	she	underwent	two	cycles	of	IVF,	resulting	in	eight	embryos	which	were	to	be	stored	until	the	uterine	transplant	was	performed	and	the	recipient	had	fully	healed.		The	transplant	was	performed	successfully	and	twenty	days	after	the	procedure	the	patient	had	her	first	menstrual	cycle.		Three	months	after	the	transplant	she	was	able	to	resume	sexual	activity.		At	the	intervals	of	four	months	and	six	months	post-transplantation	the	recipient	had	urinary	tract	infections,	but	both	infections	were	successfully	treated	by	medication	and	there	was	no	cause	for	the	removal	of	the	transplant	(Ozkan	et	al.).		The	recipient	of	the	2011	Turkish	uterus	transplant	was	the	first	uterine	transplant	recipient	in	history	to	become	pregnant.		Almost	two	years	after	the	initial	transplant	surgery	it	was	announced	that	the	recipient	was	pregnant,	but	eight	weeks	later,	during	a	routine	checkup,	the	fetal	heartbeat	could	not	be	detected	and	the	pregnancy	was	terminated.		While	doctors	stated	that	the	patient	would	resume	IVF	treatments	once	she	was	“ready”,	there	is	no	evidence	that	IVF	was	ever	resumed	and	the	uterus	was	eventually	removed.		This	transplant	was,	in	a	
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way,	successful	because	there	was	no	necrosis	of	the	uterus	or	other	obvious	signs	of	rejection	that	necessitated	immediate	removal.		While	the	researchers	boast	that	this	was	the	“first	clinical	pregnancy	in	a	patient	with	absolute	uterine	infertility”	(Ozkan	et	al),	the	procedure	itself	is	largely	considered	unsuccessful	because	it	did	not	result	in	the	birth	of	a	child.		It	was	not	until	2014,	when	a	participant	in	a	Swedish	clinical	trial	gave	birth	to	a	healthy	male	baby,	that	the	medical	community	could	finally	cite	a	successful	uterine	transplant.		The	transplant	procedure	itself	was	performed	in	2013,	when	a	35	year-old	patient	with	MRKH	(Emelie	Eriksson)	received	a	uterus	from	a	61	year-old	donor	(her	mother	Marie),	who	had	previously	given	birth	on	more	than	one	occasion.		The	donor	and	recipient	underwent	the	transplantation	procedures	at	Sahlgrenska	University	Hospital	in	Gothenburg,	Sweden.		One	year	after	the	transplant	the	recipient	had	her	first	single	embryo	transfer	(using	an	embryo	created	with	her	oocyte	and	her	husband’s	sperm),	which	resulted	in	pregnancy.		In	order	to	stave	off	rejection,	the	patient	was	put	on	a	regimen	of	triple	immunosuppression	(tacrolimus,	azathioprine,	and	corticosteroids),	which	was	continued	throughout	pregnancy.		Even	though	there	were	multiple	episodes	of	mild	rejection	(all	of	which	were	combatted	with	corticosteroid	treatment)	the	pregnancy	was	relatively	routine,	until	the	31st	week	when	the	patient	was	admitted	to	the	hospital	with	pre-eclampsia.		Hours	later	doctors	delivered	the	baby	via	caesarean	section	(Heinonen).		A	few	months	after	the	birth	of	the	child,	the	transplanted	uterus	was	removed.		The	removal	of	the	uterus	allowed	the	recipient	
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to	terminate	her	regimen	of	immunosuppressant	drugs	and	avoid	any	long-term	side	effects	associated	with	these	medications.					The	Swedish	clinical	trials	used	live	donors	(women	who	were	often	genetic	relatives	of	the	recipients),	resulting	in	seven	successful	womb	transplants	and	(as	of	April	2017)	a	total	of	five	live	births.		These	trials	have	proved	that	uterine	transplants	are	indisputably	a	viable	way	to	treat	uterine	factor	infertility	(though	we	still	don’t	know	the	long	term	effects	of	UTx	on	the	mothers	or	the	babies).		Since	the	study	in	Gothenburg,	two	different	clinical	trials	have	gotten	underway	in	the	United	States,	one	at	the	Cleveland	Clinic	in	Cleveland,	Ohio,	and	the	other	at	the	Baylor	University	Medical	Center	in	Dallas,	Texas.			Two	other	American	clinics	have	registered	for	pilot	trials,	have	been	approved	by	UNOS,	and	may	proceed	to	the	clinical	trial	stage	in	due	course.		There	have	also	been	attempts	in	China	(November,	2015)	and	in	the	Czech	Republic	(April,	2016).		In	January	2017	a	medical	team	from	Keio	University	in	Japan	applied	to	the	university’s	ethics	panel	for	approval	to	begin	offering	uterine	transplants.		Worldwide,	more	than	15	uterine	transplants	have	been	performed,	but	so	far	only	the	Swedish	trials	have	been	deemed	successful	and	have	resulted	in	live	births	(Maron,	Donated	Uterus).			On	February	24,	2016	the	surgical	team	at	the	Cleveland	Clinic	performed	America’s	first	uterine	transplant.		Screening	for	participants	began	in	September	of	2015,	and	the	preferred	demographic	included	women	aged	21-to-39	with	UFI.		These	women	were	all	required	to	be	in	stable	romantic	relationships,	they	were	required	to	show	that	they	had	enough	money	to	fund	their	travel	and	living	expenses	(Grady).			After	multiple	rounds	of	medical	and	psychological	evaluations,	
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a	panel	of	experts	chose	ten	women	to	participate	in	the	trial.		The	donors	in	this	trial	were	all	deceased	and	fell	between	the	ages	of	18	and	40	years	old.		The	first	participant	in	the	trial	to	undergo	the	transplantation	process,	26-year-old	Lindsey	McFarland,	experienced	a	successful	procedure.		While	she	and	the	surgeons	were	all	extremely	optimistic	about	the	outcome,	McFarland	only	had	her	transplanted	uterus	for	a	couple	of	weeks	before	it	was	removed,	on	March	8,	2016,	due	to	a	fungal	infection	that	compromised	blood	supply	to	the	organ	(Zeltner).		The	clinical	trial	was	temporarily	put	on	hold	(as	of	April	2017	the	trial	is	still	suspended)	while	the	team	modifies	the	protocol	in	an	attempt	to	reduce	the	risk	of	this	complication	occurring	with	the	other	nine	transplants.			Though	the	Cleveland	Clinic	trials	stalled	after	the	first	failed	transplant,	the	Baylor	clinical	trial	is	currently	ongoing.		After	a	two-year	research	initiative,	in	September	of	2016	a	surgical	team	at	the	Baylor	University	Medical	Center	performed	four	uterine	transplants	(using	live	“altruistic”	donors).		In	addition	to	the	use	of	live	donors,	the	Baylor	clinic	is	also	using	a	robot	to	assist	in	the	removal	of	the	uterus	from	the	donor,	which	shortens	the	time	in	surgery.		While	three	of	these	transplants	quickly	failed	and	required	uterine	removal,	the	uterus	in	the	fourth	patient	(as	of	April	2017)	is	still	viable.		These	first	four	transplants	are	a	part	of	a	larger	clinical	trial	of	ten	women	between	the	ages	of	20	and	35	years	old,	all	of	whom	were	born	with	MRKH	(Goodman).			Animal	trials,	specifically	those	done	with	nonhuman	primates	as	their	test	subjects	have	helped	to	determine	the	currently	accepted	transplantation	procedure	and	it’s	accompanying	medications.		All	three	of	the	modern	uterine	transplant	
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clinical	trials	work	off	of	the	same	transplant	procedural	template	that	was	developed	based	on	research	with	these	animal	models.		A	graphic	of	this	procedure	in	humans	is	available	in	Appendix	A.		Uterine	transplantation	is	a	multiple	surgery	process	and	it	entails	the	removal	of	the	donor	uterus	through	the	isolation	of	the	uterus	with	bilateral,	long	venous,	and	arterial	vascular	pedicles,	the	transplantation	of	the	uterus	into	the	recipient	and	then	(after	one	or	two	successful	pregnancies)	an	eventual	second	surgery	to	remove	the	transplanted	uterus.		After	the	transplanted	uterus	is	removed,	it	becomes	biomedical	waste	and	cannot	be	used	for	a	subsequent	transplant	recipient.		These	procedures	have	regimented	schedules	of	antirejection	medications	that	are	associated	with	them,	which	usually	include	a	combination	of	several	different	medications	at	varying	doses	depending	on	the	stage	of	the	procedure	(before,	during,	and	after	surgery,	as	well	as	different	phases	of	a	resulting	pregnancy).			
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Chapter	2	Bioethical	Considerations	of	Uterine	Transplants	and	other	ARTs	Uterine	transplantation	requires	the	examination	of	a	plethora	of	different	bioethical	standards,	as	it	involves	several	medical	topics	that	often	incite	bioethical	debate:	assisted	reproductive	technologies,	transplant	surgeries,	and	elective	procedures	(which	will	be	addressed	more	fully	in	Chapter	3).		In	addition	to	the	preexisting	controversies	in	all	of	the	aforementioned	fields,	the	uterine	transplant	is	a	markedly	unique	procedure,	and	therefore	has	garnered	critiques	and	bioethical	questions	that	are	new	and	UTx-specific.		While	the	concept	of	a	uterine	transplant	has	been	considered	for	many	decades,	and	successful	transplants	have	recently	been	conducted,	the	ethical	issues	are	so	elaborate,	that	most	western	medical	associations	are	being	slow	to	accept	the	procedure.		Even	in	cases	where	UTx	has	been	approved	and	studied,	the	development	of	a	procedural	layout	was	an	arduous	process.		Dr.	Alan	Lichtin,	of	the	Cleveland	Clinic,	said	in	an	interview	for	the	New	York	Times,	that	it	took	about	a	year	of	going	back	and	forth	before	the	research	team	could	finally	produce	a	plan	that	the	Cleveland	Clinic’s	15-member	ethics	board	would	approve	(Grady).		Assisted	reproductive	technologies,	in	general,	have	long	been	under	fire	by	those	individuals	and	organizations	that	believe	science	should	not	interfere	with	conception	(mainly	members	of	the	religious	right).		A	main	ART	that	faces	bioethical	scrutiny	is	In	Vitro	Fertilization.		IVF	is	often	used	for	another	very	controversial	ART	(gestational	surrogacy)	and	is	always	required	in	order	for	uterine	transplant	recipients	to	conceive.			
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Since	1978,	when	the	first	IVF	baby	was	born,	this	procedure	has	become	very	common	practice	in	industrialized	countries,	where	almost	10%	of	all	couples	experience	fertility	problems.		There	is	still	fear	that	this	technology	might	be	used	in	the	future	for	the	purposes	of	cloning	or	eugenics,	but	the	original	concern,	that	IVF	babies	would	be	“different”	(developmentally	or	physically)	from	naturally	conceived	babies,	has	been	generally	dispelled	by	data	analytics	over	the	past	four	decades.		With	that	fear	out	of	the	way,	most	concerns	about	IVF	are	now	less	centered	on	medical	issues	and	tend	to	focus	on	religious	and	social	objections,	as	well	as	legal	policies	regulating	the	use	of	IVF	(Banjeree).		When	a	woman	undergoes	a	cycle	of	In	Vitro	Fertilization	she	is	given	fertility	drugs	to	stimulate	oocyte	production.		After	stimulation	multiple	eggs	are	retrieved	and	fertilized	in	a	laboratory	dish.		In	most	cases,	while	many	oocytes	are	fertilized,	not	all	of	them	are	used.		Some	are	not	implanted	in	the	uterus	and	instead	might	be	frozen	for	future	implantation	or	are	donated	for	research	purposes.		Some	intended	parents	even	choose	to	have	their	excess	oocytes	buried.		Usually	several	fertilized	oocytes,	which	at	this	point	are	considered	embryos,	are	implanted	in	the	uterus	at	once,	and	if	multiple	embryos	are	successful,	the	parent	may	elect	to	terminate	one	or	more	of	the	pregnancies	to	avoid	having	a	multiple	birth.	At	this	point	the	question	of	when	life	begins	comes	into	play.		Those	who	believe	that	life	begins	when	the	sperm	fertilizes	the	egg	consider	all	embryos	to	be	human	lives,	and	therefore	take	issue	with	the	termination	or	the	freezing/donation	of	excess	embryos.		Since	it	has	been	postulated	that	only	one	out	of	every	150	IVF	implantations	results	in	a	live	birth,	those	who	view	embryos	as	alive	see	IVF	as	a	
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great	and	unnecessary	waste	of	life.		For	people	who	believe	that	life	begins	at	implantation	as	opposed	to	fertilization,	the	amount	of	perceived	death	is	lessened,	but	still	hard	to	justify	(Banjeree).			Statistics	show	that	babies	produced	through	IVF	tend	be	delivered	pre-term	and	with	low	birth	weights	as	compared	to	those	who	were	naturally	conceived,	but	these	stats	can	be	skewed	by	the	fact	that	IVF	often	produces	multiple	births,	and	even	twins,	triplets,	etc.	who	are	conceived	naturally	experience	these	issues.		However,	one	cannot	deny	that	the	increased	likelihood	of	these	complications	constitutes	added	risk	incurred	through	IVF.		Members	of	certain	religious	groups	oppose	IVF	and	other	assisted	reproductive	technologies	because	they	believe	that	God	is	the	only	one	who	should	be	able	to	control	conception	(Banjeree).		If	that	is	the	truth,	a	woman	who	is	infertile	due	to	age,	medical	complications,	or	any	other	factors,	is	not	meant	to	bear	a	child.		Many	critics	of	IVF	also	believe	that	it	should	not	be	an	option	for	doctors	or	parents	to	choose	to	not	implant	an	embryo	that	is	abnormal	(Katz	et	al.	1119-1121).		During	IVF,	some	parents	opt	for	Preimplantation	Genetic	Diagnosis	(PGD),	a	process	in	which	doctors	remove	a	cell	from	an	embryo	and	have	it	tested	for	specific	genetic	conditions,	before	implanting	it	in	womb	of	the	gestational	carrier.		Usually	if	it	is	determined	that	the	embryo	would	develop	into	a	child	with	a	negative	genetic	condition,	the	parents	chose	not	to	implant	it.		This	draws	a	lot	of	bioethical	criticism	from	pro-life	communities	and	disability	activists,	as	well	as	scholars	and	lay	people	alike	who	fear	that	PGD	is	a	stepping-stone	to	eugenics	(Morse).			
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Opponents	of	IVF	often	argue	that	if	an	infertile	couple	truly	wishes	to	have	children,	they	can	pursue	adoption	or	foster	parenting.		Critics	of	uterine	transplantation	also	use	the	existence	of	these	options	to	argue	that	UTx	is	not	necessary.		When	performing	online	research	into	UTx,	adoption	and	foster	care	are	consistently	listed	as	alternatives	to	uterine	transplants,	and	so	is	gestational	surrogacy.		If	a	woman	does	not	have	a	functional	uterus,	traditional	IVF	will	not	work	for	her.	That	said,	gestational	surrogacy,	using	an	embryo	made	from	the	oocyte	of	the	intended	mother	and	sperm	from	the	intended	father,	provides	another	avenue	for	biological	children,	as	long	as	the	intended	mother	has	functional	ovaries.		While	gestational	surrogacy	can	technically	be	achieved	through	artificial	insemination,	the	resulting	child	will	genetically	be	that	of	the	intended	father	and	the	surrogate	(with	no	genetic	relationship	to	the	intended	mother).		This	system	is	hardly	ever	used	because	it	can	create	emotional	and	legal	issues	between	the	surrogate	and	the	intended	parents.		Most	gestational	surrogacy	involves	the	intended	mother	and	father	using	IVF	to	create	embryos	that	will	then	be	implanted	in	the	uterus	of	the	gestational	surrogate.		While	surrogacy	usually	results	in	a	child	genetically	related	to	the	intended	parents,	people	from	many	different	religious,	philosophical	and	social	backgrounds	find	this	system	to	be	largely	problematic.		Additionally,	this	practice	is	not	universally	accessible,	as	several	countries	have	legally	prohibited	all	forms	of	surrogacy	(France,	Iceland,	Italy,	Pakistan,	Saudi	Arabia)	and	others	only	allow	for	altruistic	surrogacy	(Families	Through	Surrogacy).			Gestational	surrogacy,	through	the	use	of	IVF,	faces	all	of	the	same	ethical	issues	that	traditional	IVF	confronts,	and	is	additionally	considered	by	many	to	be	
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exploitative	and	akin	to	prostitution	and	human	trafficking.		Surrogacy	gets	a	lot	of	support	from	some	pro-women	organizations	and	self-proclaimed	feminists,	as	it	is	a	perfect	example	of	“women	helping	women”,	and	women	taking	their	reproductive	rights	into	their	own	hands.		Conversely,	other	pro-women	organizations	and	feminists	see	surrogacy	as	further	commodification	of	the	female	body	and	rail	against	a	system	where	the	womb	can	be	rented	out	for	a	price.		Personal	liberty	advocates	also	see	ethical	issues	with	non-altruistic	gestational	surrogacy	because	it	highlights	the	issue	of	parental	“ownership”	and	raises	the	question,	are	the	intended	parents	renting	the	surrogate’s	womb	and	time,	or	are	they	paying	money	to	purchase	a	baby	(Morse)?			The	critiques	about	unethical	practices	in	surrogacy	are	even	harsher	when	it	comes	to	“surrogacy	tourism”.		Many	parents	from	Western	countries	like	the	United	States	elect	to	have	their	genetic	babies	gestated	in	the	wombs	of	impoverished	women	in	other	countries,	like	India,	because	the	process	is	much	cheaper	and	has	less	red	tape.		The	women	in	these	countries	who	become	surrogates	usually	deal	with	negative	social	stigma	and	only	elect	to	do	so	because	they	are	desperate	for	money.		These	women	are	connected	with	intended	parents	through	brokers,	who	take	the	majority	of	the	profit,	and	often	times	the	women	(like	the	surrogates	at	the	Akanksha	clinic	in	Anand)	are	required	to	stay	in	hostels	for	the	full	nine	moths,	eat	certain	foods	and	refrain	from	most	of	their	normal	daily	tasks,	in	order	to	ensure	that	they	don’t	do	anything	to	jeopardize	the	health	of	the	child	(Bhalla).		The	surrogates	connected	with	these	organizations	are	not	even	allowed	to	spend	the	night	with	their	husbands	or	go	home	to	visit	their	children.		
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In	addition	to	the	aforementioned	problems	with	surrogacy	institutions,	the	potential	health	risks	associated	with	pregnancy	and	childbirth	are	transferred	to	the	surrogate.		Therefore,	these	women	are	not	only	getting	paid	to	dedicate	a	long	period	of	time	to	this	process,	but	also	to	put	their	mental	and	physical	health	at	risk.		The	postpartum	experience	is	difficult	for	many	women,	and	can	develop	into	postpartum	depression,	and	there	is	no	way	to	predict	how	a	gestational	surrogate	will	deal	with	these	hormonal	changes	in	conjunction	with	the	fact	that	she	will	not	even	have	a	child	to	nurse	and	raise	after	giving	birth.		In	traditional	pregnancies,	the	bond	between	mother	and	growing	fetus	is	constantly	discussed	and	reaffirmed,	but	gestational	surrogates	are	cautioned	to	remember	that	they	are	only	carrying	the	fetus,	and	they	have	no	claim	to	the	resulting	baby.		These	women	are	also	often	cast	aside	after	delivering	the	babies,	and	are	not	offered	post-partum	medical	care	or	mental	health	checkups.	While	surrogacy	challenges	traditional	ideas	about	the	significance	of	the	gestational	process,	many	women	who	desire	uterine	transplants	are	willing	to	take	on	the	discomfort	and	risk	of	multiple	surgeries	precisely	because	they	consider	the	experience	of	pregnancy,	and	the	nearly	ten-month-long	journey	of	gestation,	to	be	invaluable.		When	debating	the	ethics	of	uterine	transplantation,	much	emphasis	is	placed	on	whether	these	new	transplants	are	“worth	the	risks”	when	there	already	exists	an	extensive	list	of	options	(IVF,	surrogacy,	adoption,	and	fostering)	that	can	be	employed	by	intended	parents	with	fertility	problems.		The	counter	argument	with	this	view	is	that,	while	there	are	preexisting	assisted	reproductive	technologies	that	share	one	of	the	primary	results	of	uterine	transplants	(having	a	child),	no	
	 21	
other	technology	currently	exists	to	allow	people	without	functional	uteri	to	become	
pregnant	and	experience	gestation.		Uterine	transplantation	brings	together,	for	the	first	time,	the	medical	specialties	of	reproductive	medicine	and	transplant	surgery.		This	intersection	ensures	that	uterine	transplants	are	seeped	in	the	ethical	issues	of	both	specialties.		Dr.	Eric	Kodish,	the	director	of	the	Cleveland	Clinic’s	ethics	center,	deemed	uterine	transplantation	to	be	ethically	superior	to	surrogacy,	and	said	that	through	surrogacy,	“You	create	a	class	of	people	who	rent	their	uterus,	rent	their	body,	for	reproduction.		It	has	some	gravity.	It	possibly	exploits	poor	women.”	(Grady).		While	some	ethicists	believe	that	uterine	transplants	may	constitute	a	more	ethical	path,	that	is	not	a	universally	held	stance,	and	it	is	obvious	that	uterine	transplants	are	not	without	their	own	ethical	issues.		UTx	specific	bioethical	concerns	stem	mainly	from	the	risk	of	the	multiple	required	surgeries,	the	post-op	emotional	strain	experienced	by	the	donor	and	the	recipient,	the	need	for	immunosuppressant	medications	before	and	during	gestation,	and	the	questions	of	where	and	how	donor	uteri	will	be	procured.		Another	key	issue	is	that	the	pregnancy	and	childbirth	experiences	will	not	entirely	align	with	the	traditional	experiences,	as	a	UTx	recipient	will	be	unable	to	feel	most	fetal	movements	or	have	a	vaginal	birth.				Like	other	solid	organ	transplants,	if	the	donor	is	living,	the	surgical	risk	will	be	spread	to	both	the	donor	and	the	recipient.		For	a	live	uterine	donor,	the	operation	is	not	as	simple	as	a	standard	hysterectomy	(which	usually	takes	around	an	hour	and	a	half)	because	it	is	necessary	to	remove	part	of	the	vagina	and	other	tissue	needed	to	attach	the	uterus	to	the	recipient.		This	is	also	a	more	complex	procedure	because	
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the	uterine	vessels	are	wound	around	the	ureters,	and	the	surgeons	must	carefully	separate	them	in	order	to	retrieve	the	vessels	without	causing	damage	to	the	fragile	ureters.		Overall,	the	uterine	retrieval	process	can	take	from	7	to	11	hours	and	all	of	the	work	is	done	in	close	proximity	to	other	vital	organs.		The	transplant	surgery	is	a	slightly	shorter	process,	around	five	hours.		The	transplant	surgery	requires	the	connection	of	an	artery	and	a	vein	on	both	sides	of	the	uterus	to	the	recipient’s	blood	vessels.		The	donated	uterus	will	also	have	part	of	the	donor’s	vagina	attached,	and	that	will	be	stitched	directly	onto	the	recipient’s	vagina.	Supporting	tissue	attached	to	the	uterus	will	be	sewn	into	the	recipient’s	pelvis	to	stabilize	the	transplant.	It	is	not	necessary	to	connect	any	of	the	nerves	(Grady).			This	is	not	the	end	of	the	surgical	procedures	though,	because	as	stated	earlier,	a	uterine	transplant	is	temporary,	and	the	donor	uterus	is	supposed	to	be	removed	after	the	recipient	has	had	one	or	two	children.		This	means	that	the	intended	mother	will	have	to	go	through	yet	another	surgery.		A	UTx	recipient	who	experiences	two	successful	pregnancies	would	expect	to	have	a	total	of	four	scheduled	surgeries	during	this	process.		Though	each	specific	surgery	is	no	more	dangerous	than	the	average	surgery,	certain	academics,	such	as	Arthur	Caplan,	Professor	of	Bioethics	at	NYU,	take	issue	with	the	amount	of	risk	that	is	incurred	for	a	transplant	surgery	that	is	not	lifesaving.		In	2007,	Caplan	went	as	far	as	to	state	that	uterine	transplantation	fails	the	clinical	equipoise	test,	because	he	considers	gestational	surrogacy,	adoption	and	foster	care	to	be	valid	alternatives,	which	provide	the	same	result	(parenthood)	with	far	less	risk	to	all	parties	(Caplan	et	al.	19-20).			
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The	physical	and	emotional	recovery	after	the	uterine	transplant	procedure	can	be	very	difficult	for	both	the	donor	and	the	recipient.		Several	studies	conducted	in	2011	by	researchers	from	Pamukkale	University	showed	significant	increases	in	sexual	dysfunction	and	decreases	in	sexual	satisfaction	for	women	posthysterectomy	(Sözeri-Varma	et	al.).		Due	to	the	fact	that	this	procedure	is	irreversible,	it	is	extremely	important	to	ensure	that	all	possible	donors	are	made	aware	of	the	risks	before	committing	to	the	procedure.		In	addition	to	the	physical	changes	that	may	occur	posthysterectomy,	donors	may	also	experience	emotional	turmoil	due	to	loss	of	gender	identity	or	changes	in	sexuality	(Lefkowitz	et	al	443).		While	many	possible	donors	may	feel	that	these	side-effects	are	not	great	enough	to	stop	them	from	helping	another	woman	achieve	the	ability	to	carry	a	child,	these	emotional	and	physical	changes	can	truly	affect	the	quality	of	their	lives,	and	should	not	be	trivialized.			It	is	not	uncommon	for	organ	transplant	recipients	to	experience	identity	issues	post-transplant	(which	will	be	further	discussed	in	Chapter	3).		While	the	body	benefits	from	the	donated	organ	or,	in	the	case	of	UTx,	the	transplant	allows	for	new	opportunities	for	the	recipient,	the	recipient	might	be	unable	to	emotionally	bond	with	the	donor	organ.		This	inability	to	bond	can	cause	personality	changes,	paranoia,	and	possibly	cause	the	recipient	to	desire	the	removal	of	the	transplant.		While	there	has	not	been	any	evidence	of	this	emotional	rejection	of	uterine	transplants	thus	far,	if	a	recipient	were	to	feel	significantly	detached	and	disillusioned	with	the	donor	uterus,	she	may	run	the	risk	of	also	being	unable	to	emotionally	bond	with	a	child	who	is	gestated	in	the	donor	uterus	(Lefkowitz	et	al	
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443).		If	the	mother	lacked	an	emotional	bond	with	the	child,	and	felt	like	it	did	not	belong	to	her,	she	might	be	inclined	to	neglect	the	baby	or	cause	it	harm.		If	this	situation	were	to	occur,	it	would	be	damaging	to	the	lives	of	the	mother,	the	child	and	other	members	of	the	family.		This	is	just	one	of	many	reasons	that	psychological	examination	is	necessary	both	before	and	after	UTx.			Possibly	even	more	ethically	daunting,	if	a	UTx	recipient	became	noncompliant	with	the	anti-rejection	medication	regimen	while	still	pregnant—resulting	in	the	rejection	of	the	transplant—the	gestating	fetus	would	most	likely	be	lost.		At	this	point	in	time	in	the	United	States,	pregnant	women	can	be	legally	prosecuted	for	unhealthy	behaviors	that	could	cause	(or	have	caused)	harm	to	a	gestating	fetus	(Boudreaux).		If	a	uterine	transplant	recipient	were	to	neglect	her	medication,	resulting	in	the	loss	of	the	donor	uterus	and	the	fetus,	there	is	no	way	to	know	how	the	law	would	handle	the	situation,	but	it	could	go	so	far	as	to	consider	the	situation	a	fetal	homicide.			It	is	important	to	consider	both	of	these	possible	consequences	when	performing	the	risk	analysis	of	uterine	transplants.		Another	risk	to	the	psychological	well-being	of	the	recipient	stems	from	the	fact	that	another	person	needs	to	undergo	risky	and	irreversible	life-altering	surgery	in	order	to	help	them	achieve	their	goal.		Whether	this	person	is	a	relative	of	theirs,	or	an	anonymous	stranger,	there	is	risk	that	the	guilt	or	shame	of	including	another	person	in	their	reproductive	journey	could	lead	to	emotional	problems.		If	the	donor	is	involved	in	the	life	of	the	recipient,	and	subsequently	suffers	from	complications	due	to	the	surgery,	there	could	be	a	large	amount	of	strain	of	their	interpersonal	relationship	(Lefkowitz	et	al	443).			
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Ever	since	general	transplant	surgeries	(ie.	Kidney,	liver,	etc)	became	such	common	practice	there	has	been	a	lot	of	research	into	the	negative	effects	of	gestating	a	fetus	while	on	immunosuppressant	medications.		Due	to	all	of	this	research,	there	is	now	a	deep	body	of	evidence	and	literature	that	demonstrates	the	absence	of	a	statistically	significant	increase	in	malformations	or	disabilities	in	newborns	that	were	gestated	by	women	in	the	post-transplant	setting	of	solid	organs	(Lefkowitz	et	al.	441).		This	being	said,	research	has	shown	that	solid	organ	transplant	recipients	are	at	increased	risk	of	a	large	number	of	different	cancers,	due	to	the	immunosuppression	medications.		Transplant	recipients	have	been	shown	to	acquire	non-Hodgkin	lymphoma	(NHL)	and	cancers	of	the	lung,	kidney,	and	liver	at	higher	rates	than	members	of	the	general	population.		NHL	and	liver	cancer	can	be	caused	by	Epstein-Barr	and	chronic	infection	with	the	hepatitis	B	and	C	viruses,	respectively,	while	lung	and	kidney	cancers	are	not	generally	thought	to	be	associated	with	infection	(McLaughlin-Drubin	and	Munger	12-18).		Dr.	Tzakis,	from	the	Cleveland	Clinic,	remarked	that	thousands	of	women	with	kidney	and	liver	transplants	have	given	birth	to	healthy	babies,	and	while	transplant	recipient	mothers	are	more	likely	than	others	to	have	pre-eclampsia	and	smaller	babies,	it	is	not	known	whether	those	problems	are	caused	by	immunosuppressants,	or	by	the	original	illnesses	that	necessitated	the	transplants	(Grady).			Though	there	are	clearly	some	added	risks	from	taking	immunosuppressants,	reports	from	the	National	Transplantation	Pregnancy	Registry	(NTPR)	strongly	support	maintenance	of	immunosuppression	combination	therapy	regimens	during	pregnancy,	and	one	can	interpret	these	reports	as	negating	the	claim	that	
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immunosuppression	drugs	required	for	uterine	transplants	constitute	an	unethical	risk	for	the	mother	and	the	fetus	(Lefkowitz	et	al	441).		While	the	immunosuppressants	are,	of	course,	vital	to	stave	off	rejection	of	the	transplanted	uterus,	the	risk	of	post-implantation	rejection	must	be	carefully	examined.		A	very	intriguing	question	was	brought	up	by	Dr.	Alexander	Maskin,	from	the	University	of	Nebraska,	“what	happens	if	there	is	a	fetus	in	the	[transplanted]	uterus,	and	you	have	to	take	that	uterus	out?”	(Pondrom,	Uterus	Transplants	375).			Depending	on	the	stage	of	the	pregnancy,	and	personal	beliefs	about	when	life	begins,	the	removal	of	a	transplanted	uterus	with	a	fetus	could	constitute	loss	of	human	life.		There	is	also	no	way	to	quantify	the	emotional	trauma	that	would	be	experienced	by	a	recipient	who	lost	both	her	transplanted	uterus	and	her	fetus,	due	to	rejection.			Even	when	a	uterine	transplant	is	successful,	the	pregnancy	experience	is	markedly	different	than	a	traditional	pregnancy.		A	discussion	of	normalcy	will	come	up	in	Chapter	3,	and	I	feel	the	need	to	distinguish	here	that	while	(to	many	people)	pregnancy	is	considered	a	normal	part	of	a	woman’s	life,	no	part	of	a	UTx	pregnancy	is	normal.		It	is	extremely	important	for	any	potential	uterine	transplant	recipients	to	be	fully	informed	about	the	limitations	of	the	procedure,	so	they	do	not	elect	to	have	the	transplant	because	they	believe	that	it	will	give	them	the	complete	pregnancy	experience.		During	the	uterine	transplant,	the	recipient’s	fallopian	tubes	are	not	connected	to	the	transplanted	uterus,	which	means	that	a	uterine	transplant	recipient	will	not	be	capable	of	becoming	pregnant	naturally.		Recipients	will,	instead,	undergo	IVF.		Since	researchers	are	unsure	if	a	donated	uterus	can	support	multiple	births,	only	one	embryo	is	implanted	in	the	uterus	per	cycle.		When	there	is	
	 27	
a	successful	IVF	pregnancy,	the	gestational	experience	itself	is	also	altered.		The	transplanted	uterus	does	not	have	all	of	the	nerves	(because	these	nerves	are	not	vital	to	the	health	of	the	uterus)	and	therefore	women	with	transplanted	uteri	will	not	feel	contractions	in	the	traditional	way.		This	lack	of	nerve	connection	also	makes	it	harder	for	them	to	feel	the	fetal	movement	within	the	womb,	including	when	the	fetus	kicks	(Grady).		Transplant	recipients	will	always	have	their	babies	delivered	via	cesarean	section,	so	there	is	no	chance	of	a	recipient	experiencing	vaginal	birth	(Maron,	Donated	Uterus).		The	children	gestated	in	donated	uteri	will	always	be	delivered	slightly	prematurely,	so	as	to	avoid	fully	stretching	the	uterus.		Premature	babies	are	more	likely	to	have	health	issues	than	full	term	babies,	so	this	added	risk	must	be	acknowledged.			The	Montreal	Criteria	for	the	Ethical	Feasibility	of	Uterine	Transplantation	provide	a	comprehensive	list	of	criteria	that	the	authors	believe	must	be	met	in	order	for	a	uterine	transplant	to	be	ethically	performed	at	this	time.		These	criteria	can	serve	as	a	good	framework	when	moving	forward	with	UTx	clinical	trials,	but	they	are	not	equally	accepted	by	all	research	teams	and	can	be	altered	for	better	applicability.			The	Montreal	Criteria	specifically	outline	the	different	standards	that	must	be	met	in	order	for	a	woman	to	be	considered	as	a	uterine	transplant	recipient	or	donor,	and	also	provides	a	model	to	be	followed	by	any	healthcare	team	that	wishes	to	perform	this	procedure.		Some	of	the	main	guidelines	are	that	the	recipient	must	be	a	genetic	female	with	a	documented	case	of	UFI,	the	donor	must	be	a	female	of	reproductive	age	who	has	repeatedly	insisted	that	she	desires	the	end	of	her	fertility,	and	the	health-care	system	must	provide	sufficient	informed	consent	
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to	both	parties	(Lefkowitz	et	al	442-443).		These	criteria	have	not	been	strictly	followed	by	all	transplant	teams,	as	the	Swedish	trial	used	several	donors	who	were	past	reproductive	age,	but	I	believe	that	they	provide	a	good	indication	of	how	UTx	will	be	regulated	in	the	future.		Excerpts	from	the	Montreal	Criteria	for	the	Ethical	Feasibility	of	Uterine	Transplantation	are	available	in	Appendix	B.			Much	of	the	debate	over	the	ethics	of	uterine	transplantation	is	due	to	the	principles	of	autonomy	and	nonmaleficence.		The	principle	of	nonmaleficence	is	more	colloquially	stated	in	the	Hippocratic	Oath	as	“do	no	harm”.		While	physicians	vow	not	to	bring	harm	to	their	patients	(and	performing	a	risky	procedure	like	a	uterine	transplant	for	reasons	that	are	not	life-saving	could	be	seen	as	constituting	harm),	the	principle	of	autonomy	would	argue	that	a	person	should	be	able	to	make	their	own	decisions	about	which	risks	they	are	willing	to	take.			In	the	case	of	the	uterine	transplant,	according	to	The	Montreal	Criteria	for	the	Ethical	Feasibility	of	Uterine	Transplantation,	a	woman’s	desire	to	reproduce	and	the	right	to	reproductive	self-determination	(which	is	derived	from	the	principle	of	autonomy)	exerts	an	ethical	obligation	on	the	medical	community	to	attempt	to	help	her	achieve	her	reproductive	goals.		Physicians	involved	in	uterine	transplantation	are	required	to	analyze	the	potential	psychosocial	benefits	that	can	be	obtained	through	UTx,	and	then	compare	them	to	the	physical	and	emotional	risks	that	a	recipient	would	have	to	undertake	in	order	to	achieve	those	benefits	(Lefkowitz	et	al	446).		As	in	a	normal	cost-benefit	analysis,	if	the	psychosocial	benefits	outweigh	the	potential	costs	(risks),	the	procedure	is	deemed	ethical.	It	is	clear	that	in	certain	clinics,	where	these	trials	are	underway,	researchers,	clinical	trial	administrators	
	 29	
and	the	IRB	believe	that	all	of	the	risks	(which	have	been	outlined	in	this	chapter)	can	be	mitigated	by	strict	procedural	guidelines	and	justified	by	the	potential	benefits	that	uterine	transplants	can	bring	to	women	with	UFI.			****	There	are	many	circumstances	that	might	arise	if	UTx	is	approved	that	I	have	not	had	time	to	discuss	and	analyze	in	this	chapter.		It	is	possible	that	a	UTx	recipient	might	refuse	to	have	the	donor	uterus	removed	after	childbirth,	or	that	a	patient	might	desire	a	uterine	transplant	but	not	wish	to	use	that	uterus	for	the	purpose	of	gestation.		It	is	also	possible	that	a	recipient	might	get	pregnant	and	then	desire	an	abortion.		Each	of	these	situations	would	raise	questions	about	the	ethicality	of	UTx,	the	purpose	of	the	procedure	and	the	autonomy	of	the	women	who	would	undergo	transplantation.		While	these	questions	are	important,	they	did	not	fit	well	into	this	specific	thesis	and	I	have	not	chosen	to	speculate	about	how	the	IRB	would	rule	on	these	scenarios.					 												
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Chapter	3	Precedent	for	Quality-of-Life	Procedures			While	uterine	transplants	are	currently	experiencing	bioethical	scrutiny,	the	human	uterine	transplant	is	by	no	means	the	first	medical	procedure	designed	to	address	a	health	problem	that	is	not	strictly	life-threatening.		There	are	several	other	quality-of-life	procedures	that	undergo,	or	have	previously	undergone,	similar	bioethical	investigations.		In	this	chapter,	I	have	decided	to	examine	hand,	face	and	penile	transplants.	While	all	of	these	surgical	operations	can	be	considered	“quality-of-life”	procedures,	there	is	a	gradient	of	social	acceptability	that	speaks	to	which	physical	qualities	are	more	highly	valued.		Finally,	it	is	largely	important	to	identify	and	scrutinize	the	motivations	for	all	of	these	procedures.		We	must	determine	if,	and	in	which	ways,	these	procedures	improve	the	lives	of	the	patients.		If	these	quality-of-life	procedures	do	not	actually	serve	the	purpose	of	bettering	the	lives	of	the	individuals	who	undergo	them,	it	could	be	true	that	they	do	more	to	serve	the	societal	desire	for	uniformity	than	to	serve	the	patient/recipient.			Quality-of-life	transplants	are	not	a	new	concept,	and	this	is	demonstrated	by	the	legends	and	stories	about	limb	and	tissue	transplants	that	have	existed	for	over	a	thousand	years.	‘The	legend	of	the	black	leg’	(Leggenda	Aurea)	is	an	account	of	two	twin	brothers,	Cosmas	and	Damian,	who	supposedly	replaced	the	diseased	leg	of	a	sleeping	man	with	a	leg	recovered	from	a	dead	Ethiopian	Moor,	in	348	CE.		There	are	tales,	also,	of	the	father	of	modern	plastic	surgery,	Gaspare	Tagliacozzi,	transplanting	the	nose	of	a	slave	to	his	master	in	the	16th	century	(Gander	et	al.	869).		In	the	1900s	limb	transplants,	and	even	head	transplants,	were	attempted	on	
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animals	and	all	of	these	studies	helped	to	lay	the	groundwork	for	human	allotransplantation.		The	first	successful	corneal	transplant	(a	quality-of-life	procedure	to	restore	vision)	was	performed	over	100	years	ago	in	1905	(Armitage	1222).		Almost	sixty	years	later	the	first	hand	transplant	was	attempted	in	Ecuador	(unsuccessfully)	and	in	1999	a	hand	transplant	was	successfully	performed	on	Clint	Hallam,	a	New	Zealander	who	had	lost	his	hand	in	a	prison	accident.		After	the	hand	transplant,	members	of	the	medical	community	immediately	set	their	sights	on	face	transplants,	and	within	six	years	the	first	partial	face	transplant	was	performed	on	the	victim	of	a	vicious	dog	attack.		While	these	procedures	are	far	from	common,	they	have	been	accepted	and	mainly	praised	because	they	increase	the	quality-of-life	of	their	recipients.		The	success	of	the	face	transplant	has	demonstrated	the	scope	of	possible	transplant	procedures	and	now	researchers	and	surgeons	are	studying	and	attempting	penile	transplants.		At	this	point,	over	85	patients	have	received	hand	or	arm	transplants	at	various	different	institutions	around	the	world.		The	longest	surviving	hand/arm	transplant	is	11	years	old	and	it	belongs	to	the	first	US	patient	to	receive	one.		Recipients	of	hand	transplants	must	have	had	a	below	the	shoulder	amputation	of	one	or	both	arms,	or	suffer	from	the	severe	deformity	of	one	or	both	arm/hands.		Even	though	these	transplants	have	moved	past	the	clinical	trial	stage,	there	are	still	strict	parameters	that	a	transplant	recipient	must	meet,	such	as	having	no	history	of	HIV	or	hepatitis	C,	being	cancer	free	for	at	least	five	years,	and	a	willingness	to	forgo	pregnancy	for	one	year.		The	recipient	must	also	be	older	than	18	and	younger	than	65.		This	procedure	is	relatively	low	risk,	but	while	Johns	Hopkins	Hospital	states	
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“no	patient	taking	his/her	immunosuppression	drugs	on	time	and	as	advised	has	lost	a	transplanted	hand/arm”	(Lee,	Hand/Arm),	the	clinic	neglects	to	mention	that	post-operative	non-adherence	has,	in	many	cases,	been	associated	with	rejection	episodes,	graft	loss,	and	even	death	(Kumnig	et	al.	574).		Often-times,	the	reasons	for	patient	non-adherence	stem	from	psychological	issues,	most	notably	identity	problems	that	result	from	patients	attempting	to	reconcile	the	fact	that	a	piece	of	their	body	used	to	belong	to	someone	else.		In	one	case,	a	transplant	recipient	found	out	the	identity	of	his	organ	donor,	and	was	so	upset	by	the	situation	that	he	committed	suicide	(Zhang	et	al.	798).			Even	though,	in	addition	to	the	matching	of	blood	type	and	immunological	parameters,	the	recipient/donor	matching	process	involves	an	emphasis	on	matching	skin	color,	skin	texture,	gender,	ethnicity/race,	and	the	size	of	the	hand	or	arm,	it	is	impossible	to	find	a	“perfect”	physical	match.		The	fact	that	the	transplant	will	most	likely	be	perceptibly	different	from	the	rest	of	the	recipient’s	body	is	usually	not	a	problem,	but	in	some	cases	it	can	wreak	emotional	havoc.		In	order	to	avoid	these	identity	problems	as	much	as	possible,	it	is	important	to	psychologically	evaluate	potential	transplant	recipients,	and	look	for	warning	signs	of	eventual	non-compliance,	such	as	premorbid	psychiatric	status,	poor	social	support,	substance	abuse	and	pre-operative	noncompliance	(Kumnig	et	al.	574).			The	potential	loss	of	personal	identity	could	be	even	more	likely	when	considering	face	transplants,	as	the	face	is	so	strongly	linked	to	one’s	personal	sense	of	self.		Since	2005,	more	than	20	patients	have	received	full	or	partial	face	transplants	at	institutions	around	the	world	(Lee).		Once	again	it	seems	that	a	face	
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transplant	has	yet	to	be	fully	rejected	by	a	patient	who	complied	with	the	post-operative	regimen	as	set	by	the	surgeons,	and	in	this	case,	reports	show	that	there	has	not	been	the	same	issue	of	noncompliance	as	seen	with	some	of	the	hand	transplant	recipients	(most	notably	Clint	Hallam,	who’s	hand	was	removed	three	years	after	the	initial	transplant).			This	difference	could	result	from	the	fact	that	a	face	transplant	does	not	make	the	recipient	look	like	a	photocopy	of	the	donor.		Instead,	face	transplant	recipients	will	look	neither	exactly	like	their	original	selves	nor	like	the	donor.		Due	to	the	bone	structure	of	the	recipient	under	the	donors	face,	they	will	have	a	composite	identity	(Freeman	et	al.	78).		While	face	transplant	recipients	will	surely	need	to	adjust	to	their	new	identities,	they	can	more	easily	reconcile	their	changed	appearance	because	they	are	not	simply	taking	the	appearance	of	the	dead	donor.			“Penile	transplantation	shares	similar	considerations	as	face	transplantation,”	says	Dr.	Redett	of	Johns	Hopkins.		“It	involves	a	part	of	the	body	that	is	uniquely	personal	in	nature	and	strongly	associated	with	one’s	sense	of	self	and	identity	as	a	male”	(Pondrom,	Penile	Transplant	376).		The	penile	transplant	is	a	new	procedure,	though	it	has	been	desired	by	men	who	have	lost	their	penises	for	decades.		The	surgery	lasts	10	to	12	hours	and	involves	the	connection	of	a	minimum	of	two	nerves,	two	veins	and	four	arteries.		Similar	to	hand	transplants,	penile	transplants	do	more	than	just	replace	a	part	of	the	body	that	is	now	missing.		A	successful	penile	transplant	allows	the	recipient	to	gain	an	erection,	perform	penetrative	sexual	intercourse	and	ejaculate.		Penile	transplants	and	personal	identity	are	strongly	linked,	but	in	contrast	to	hand	and	face	transplants	it	seems	that	the	penis	
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transplant	is	more	likely	to	restore	personal	identity	than	to	challenge	it.		While	there	will	of	course	be	the	same	struggle	to	find	a	“perfect	match”	to	the	recipient’s	skin	tone	and	body	type,	the	transplant	will	not	be	visible	to	society	at	large,	so	differences	in	those	factors	may	not	cause	as	big	of	a	problem.			While	all	of	the	quality-of-life	procedures	that	have	been	examined	in	this	chapter	have	certain	levels	of	risk,	they	have	been	approved,	performed,	and	embraced	(by	many)	in	the	United	States.		The	fact	that	these	surgeries	exist	sets	a	substantial	precedent	for	uterine	transplants,	as	they	serve	the	same	function	and	incur	similar	risks,	all	for	the	overarching	goal	of	perceived	normality.			I	say	that	the	general	goal	for	all	of	these	procedures	is	perceived	normality,	and	that	claim	is	based	on	my	investigation	into	the	motivations	of	each	of	these	surgeries.		According	to	interviews	performed	by	Martin	Kumnig	and	his	colleagues,	though	the	motivation	for	hand	transplantation	in	bilateral	amputees	is	mainly	the	need	for	increased	function,	when	the	patient	has	only	lost	one	hand,	the	majority	of	their	motivation	stems	from	the	desire	to	correct	their	“disturbed	body	image”	(Kumnig	et	al.	574-576)	and	regain	their	original	sense	of	psychological	and	social	well-being.		Researchers	from	Transplant	International	stated	that	many	patients	who	have	had	hands	amputated	experience	self-consciousness	about	their	conspicuous	physical	differences	from	nonaffected	people	and	as	a	result	experience	an	increased	level	of	shame	when	in	public	spaces	(Kumnig	et	al.	575).		By	receiving	the	hand	transplant,	they	can	eliminate	a	level	of	perceptible	physical	difference	and	return	to	a	state	of	near	normality.			
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Similarly,	at	a	press	conference	one	year	post-op,	Mississippi	firefighter	Patrick	Hardison,	who	underwent	the	world’s	most	extensive	face	transplant,	explained	that	the	procedure	has	allowed	him	to	walk	down	the	street	without	people	staring	and	children	being	frightened.		Elated	he	explained,	“I’m	pretty	much	back	to	being	a	normal	guy,	doing	normal	activities”(Cha).		Examinations	into	the	ethicality	of	penile	transplants	also	reveal	a	large	focus	on	regaining	normality.	In	an	argument	for	penile	transplants	in	the	Asian	Journal	of	Andrology,	Li-Chao	Zhang	and	her	colleagues	state	that,	“In	a	society	that	values	'normalcy'	and	rejects	'abnormality,'	having	a	penile	defect	is	not	an	insignificant	matter.”		They	go	on	to	explain	that	the	patients	they	spoke	with	“were	commonly	'extremely	concerned'	about	how	their	defect	would	affect	their	status	in	their	family	and	in	society”	(Zhang	et	al.	796).			It	seems	that	though	these	procedures	are	flouted	as	“quality-of-life”,	the	main	way	that	they	increase	that	quality	is	to	bring	patients	back	into	the	realm	of	bodily	normality,	which	has	been	set	by	societal	standards.		Though	the	process	that	is	undergone	to	achieve	these	“fixed”	physical	appearances	is	rare	and	abnormal,	in	the	end	the	recipient	can	be	seen	by	others	as	looking	“normal”	as	opposed	to	being	deformed	or	lacking	a	part	of	their	body.		While	this	“normal	is	key”	mentality	is	disturbing,	it	can	be	used	to	provide	support	for	the	“necessity”	of	uterine	transplants	because	many	societies,	including	the	USA	and	Sweden,	consider	very	few	things	to	be	more	normal,	or	more	acceptable,	than	a	pregnant	woman.		As	soon	as	I	was	visibly	and	clearly	pregnant,	I	felt,	for	the	first	time	in	my	adolescent	and	adult	life,	not-guilty.		The	atmosphere	of	approval	in	which	I	was	bathed—even	by	strangers	in	the	street,	it	seemed—was	like	an	aura	I	carried	with	me,	in	which	doubts,	fears,	misgivings,	met	with	absolute	denial.		This	is	what	women	have	always	done.	(Rich	26)	
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Uterine	transplants	are	very	much	in	demand,	in	fact,	since	the	first	successful	uterine	transplant	in	Sweden	Dr.	Brännström	receives	around	50	emails	per	day	from	women	requesting	the	surgery.		In	addition	to	the	requests,	the	emails	usually	include	very	heartfelt	and	sad	personal	narratives	about	why	each	individual	“needs”	the	procedure	(Pondrom,	Uterus	Transplants).		In	an	interview	discussing	the	negative	psychological	effects	of	UFI,	Dr.	Farrell	proclaimed	that,	“Uterine	Factor	Infertility	can	have	a	profound	impact	on	every	aspect	of	a	woman’s	life,	from	the	time	the	diagnosis	is	made	in	adolescence	onward,”	she	says,	“It	affects	how	a	woman	views	herself	and	enters	relationships.”		She	went	on	to	explain	that	this	negative	impact	is	reason	enough	to	justify	UTx,	“It’s	not	lifesaving,	but	it	can	be	life-altering”	(Ethical	Considerations	Paramount	in	Uterine	Transplant).		Dr.	Brännström	echoed	this	sentiment	as	he	discussed	the	experiences	of	his	patients	post-UTx,	“Some	of	them	are	30	or	32	and	they’ve	never	had	a	period	before,	and	they	think	it’s	so	fantastic,”	he	stated.	“They	say,	‘Now	I	feel	like	a	real	woman’”	(Medew	and	Orange).	What	proponents	of	UTx	typically	tend	to	gloss	over	is	the	fact	that	women	are	so	adversely	affected	by	UFI,	hysterectomies,	and	infertility	as	a	whole,	because	of	the	pressure	to	conceive	naturally.		Women	are	taught	at	a	very	young	age	that	their	anatomy	defines	them.		“Women”	have	vaginas	and	uteri	and	because	of	those	physical	attributes	they	have	the	ability	to	gestate	children,	give	birth	to	them	and	then	nourish	them	with	breast	milk.		Not	only	are	they	able	to	do	those	things,	but	they	are	expected	to,	because	the	most	womanly	thing	an	individual	can	do	is	carry	a	child	and	become	a	mother.		This	rhetoric	also	equates	womanhood	with	fertility,	
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because	a	girl	does	not	“become	a	woman”	until	she	begins	menstruating,	and	to	some,	you	are	not	a	real	woman	until	you	are	a	mother,	or	on	the	path	to	achieving	motherhood.					“In	the	experience	of	the	pregnant	woman,	this	weight	and	materiality	often	produce	a	sense	of	power,	solidity,	and	validity.		Thus,	whereas	our	society	often	devalues	and	trivializes	women,	regards	women	as	weak	and	dainty,	the	pregnant	woman	can	gain	a	certain	sense	of	self-respect”	(Young	53).				 It	makes	sense	that	women	would	believe	that	the	lack	of	a	uterus,	and	therefore	the	inability	to	achieve	the	type	of	self-respect	that	Iris	Young	describes	in	the	quote	above,	would	lower	their	quality-of-life.		By	going	under	the	knife	and	receiving	a	donated	uterus,	an	“abnormal”	woman	can	reclaim,	or	claim	for	the	very	first	time,	her	normalcy.		Though	this	glorification	of	“normal	bodies”	and	the	value	placed	on	gender	roles	in	society	are	both	destructive	forces	in	the	lives	of	women	(and	people	of	all	identities),	they	have	a	very	real	impact	on	quality-of-life.		Since	women	are	forced	to	live	within	a	society	that	idolizes	normality	and	pregnancy,	they	should	have	access	to	UTx	because	it	will	help	them	gain	a	social	power	that	they	have	been	denied,	even	if	that	power	is	only	temporary.			While	all	three	of	the	previously	mentioned	transplants	(hand,	face	and	penis),	are	quality-of-life	procedures,	they	have	extremely	different	levels	of	surgical	and	ethical	complexity	and	tend	to	involve	differing	levels	of	physical	and	emotional	risk.		Though	uterine	transplants	are	also	quality-of-life	transplants	they	stand	apart	from	the	others	for	multiple	reasons,	but	the	most	important	one	might	be	that	they	don’t	require	a	dead	donor.		Though	some	clinical	trials	(like	the	Cleveland	Clinic)	are	using	cadaver	uteri,	the	only	successful	uterine	transplants	have	come	from	
	 38	
living	donors.		All	quality-of-life	transplants	involve	the	recipient	taking	on	surgical	risk	for	non-life-saving	reasons,	but	UTx	is	the	only	one	thus	far	that	also	involves	a	live	donor	incurring	risk.		While	the	other	procedures	I	have	described	are	permanent,	uterine	transplants	are	designed	to	be	temporary.		Additionally,	while	face	and	hand	transplants	are	visible	to	anyone	who	comes	in	contact	with	the	recipient	(and	penile	transplants	can	be	visually	detected	by	individuals	who	engage	in	sexual	relations	with	the	recipients),	no	one	can	see	a	uterine	transplant.		In	this	way,	UTx	might	be	considered	more	similar	to	a	kidney	or	liver	transplant	than	to	a	hand/face/penis	transplant.		Due	to	these	differences,	the	justification	for	the	uterine	transplants	clearly	must	be	different,	but	that	does	not	mean	that	the	justification	is	not	valid.			
	
	
	
	
	
	
	
	
	
	
	
	
	
	 39	
Chapter	4	Moving	Forward	with	UTx		I	have	examined	the	ethical	dilemmas	associated	with	uterine	transplantation	and	discussed	them	within	the	context	of	other	assisted	reproductive	technologies	and	quality-of-life	procedures.		While	I	find	it	clear	that	there	are	ethical	issues	with	uterine	transplantation	(including	mental	and	physical	risk	to	the	fetus	and	mother,	accessibility,	and	the	altered	gestational	experience),	the	procedure	offers	more	possible	benefits	than	risks,	for	those	who	might	seek	it	out.		When	the	medical	community	generally	accepted	non-life-saving	transplants,	such	as	hand	and	face	transplants,	it	set	a	precedent	for	other	quality-of-life	procedures,	including	UTx.		First-hand	accounts	from	UTx	recipients	like	Emelie	Eriksson,	the	first	woman	to	give	birth	to	a	uterine	transplant	baby,	and	even	Lindsay	McFarland	(who	experienced	a	failed	transplant)	are	extremely	positive	about	the	procedure	and	both	women	have	expressed	the	desire	to	see	the	UTx	become	available	for	“everyone	that	needs	it”	(Larsson).			Due	to	the	fact	that	UTx	has	been	successfully	performed,	widely	sought	out,	and	considered	ethical	by	multiple	hospital	Institutional	Review	Boards	(IRBs),	I	believe	that	uterine	transplantation	will	be	approved,	and	become	a	part	of	the	American	medical	system,	within	a	decade.		While	it	is	easy	to	foresee	a	future	for	UTx,	it	is	difficult	to	conceptualize	the	path	that	uterine	transplantation	will	follow	if	or	when	it	moves	past	the	clinical	trial	phase.		Currently	there	are	active	trials	using	live	donors	(Baylor)	and	dead	donors	(Cleveland	Clinic)	and	there	is	also	the	potential	
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option	of	3D	printed	uteri,	which	would	eliminate	the	need	for	human	donors	all	together.			At	this	point,	there	has	been	no	official	success	with	the	use	of	uteri	harvested	from	dead	donors.		I	believe	that	if	there	is	no	change	in	this	trend,	the	medical	community	will	move	forward	with	a	transplantation	model	revolving	around	live	donors.		In	this	case,	it	will	be	extremely	important	to	establish	strict	guidelines	for	achieving	informed	consent	by	the	donors.		All	potential	uterine	donors	will	need	to	understand	the	possible	risks	to	their	physical	and	mental	well-being.		Donors	must	also	be	acutely	aware	of	the	fact	that	the	procedure	is	irreversible	and	that	they	will	never	be	able	to	gestate	again.		Finally,	it	will	be	imperative	for	all	donors	to	understand	that	upon	donation	they	give	up	all	rights	to	the	organ.		The	donor	must	know	that	they	will	not	be	a	genetic	contributor	to,	or	have	legal	claim	to,	any	resulting	children.		There	will	also	have	to	be	different	protocols	for	living	unrelated	donors	and	living	related	donors.			The	issue	of	informed	consent	will	also	arise	if	uterine	transplantation	from	dead	donors	proves	to	be	viable.		In	the	trials	at	the	Cleveland	Clinic,	uteri	are	being	retrieved	from	organ	donors	whose	family	members	specifically	approved	the	donation	of	the	uterus	(Grady).		This	was	deemed	acceptable	by	the	IRB	in	the	case	of	the	Cleveland	trial,	but	the	system	is	problematic	because	there	is	no	way	to	be	certain	that	the	dead	donor	would	have	approved	of	the	donation	of	her	uterus.		As	Arthur	Caplan	and	his	colleagues	mentioned	in	Moving	the	Womb,	their	2007	warning	against	uterine	transplantation,	very	few	women	who	consent	to	be	organ	donors	ever	imagine	that	their	uterus	could	be	one	of	the	organs	transplanted	into	a	
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recipient	(Caplan,	19).		Currently,	when	registering	as	an	organ	donor,	an	individual	is	able	to	pick	and	choose	which	organs	they	feel	comfortable	donating	after	death	(HRSA).	If	uteri	are	going	to	be	harvested	from	dead	donors,	they	will	need	to	be	added	to	the	organ	donor	registry	in	order	to	ensure	that	organ	donors	are	made	aware	of	the	potential	removal	and	donation	of	their	uteri	before	they	die.			In	June	of	2016	The	United	Network	for	Organ	Sharing	(UNOS)	transplant	board	approved	the	incorporation	of	uterine	transplants,	along	with	seven	other	Vascularized	Composite	Allograft	transplants,	into	their	registry	(Levin	&	Wholley).		Currently	there	are	6	uterine	transplants	on	the	Transplants	by	Organ	Type	January	
1,	1988	-	March	31,	2017	list	and	there	is	one	transplant	candidate	on	the	waiting	list	(Data	|	UNOS).		While	UNOS	has	been	quick	to	cover	this	new	procedure,	the	organization	has	yet	to	publish	UTx-specific	guidelines	for	the	allocation	of	transplants.		Uterine	transplantation	does	not	fit	into	the	traditional	UNOS	allocation	system—which	numerically	ranks	transplant	candidates,	often	considering	length	and	severity	of	illness	and	life	expectancy	without	the	transplant.		With	non-life-saving	transplants	like	uterine,	face	and	hand	transplants	the	allocation	list	will	have	to	be	organized	differently,	most-likely	culminating	in	a	system	where	all	transplant	candidates	who	are	compatible	with	the	donor	(due	to	blood	type	and	other	medical	factors)	are	put	on	a	list	and	then	the	transplants	are	distributed	on	a	first-come	first-serve	basis.			While	current	research	into	UTx	will	surely	be	aided	by	either	deceased	donation	or	live	donation	(or	some	combination	of	the	two),	the	promising	work	on	3D	organ	printing	may	one	day	become	applicable	to	the	UTx	process.		Currently,	3D	
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models	of	organs	can	be	printed	to	aid	in	educational	demonstrations	and	to	allow	surgeons	to	rehearse	difficult	procedures,	but	experts	expect	that	it	could	be	decades	before	3D	bioprinting	(using	a	bioink	composed	of	tissue	or	human	cells	to	produce	functioning	body	parts)	progresses	enough	to	develop	fully	functioning	organs	(Pondrom,	3D	Printing	1339).		If	full-organ	bioprinting	is	ever	achieved,	uterine	transplantation	could	be	practiced	without	the	use	of	a	donor,	deceased	or	living,	and	the	organ	would	be	perfectly	tailored	to	the	recipient.		While	bioprinting	is	also	bioethically	complicated,	this	application	could	combat	many	of	the	perceived	issues	with	uterine	transplantation	(risk	for	the	donor,	the	necessity	of	immunosuppressant	drugs	while	gestating,	and	the	eventual	removal	of	the	transplant).			In	addition	to	future	changes	in	the	way	that	donor	uteri	will	be	procured,	it	is	very	possible	that	the	pool	of	UTx	recipients	will	also	expand	in	the	coming	years.		While	modern	research	is	focused	on	cis-women	who	lack	uteri,	a	strong	interest	in	uterine	transplants	has	been	expressed	by	trans	communities,	and	many	researchers	are	already	considering	bring	trans	individuals	into	the	fold.		While	it	is	difficult	to	find	academic	literature	discussing	UTx	in	trans	patients,	social	networking	forums	like	Tumblr	and	Reddit,	as	well	as	popular	media	websites	such	as	the	Huffington	Post,	have	discussed	this	possibility.		When	approached,	several	researchers	have	postulated	that	it	will	be	possible	to	perform	uterine	transplantation	on	trans-women	within	the	next	two	decades.		Some	professionals	are	even	more	optimistic.		In	November	of	2015	Dr.	Karine	Chung,	director	of	the	fertility	preservation	program	at	the	University	of	Southern	California’s	Keck	School	
	 43	
of	Medicine,	stated	that	the	procedure	would	be	possible	within	five	to	ten	years	(Gordon).		The	lag-time	between	trials	with	cis-females	and	trials	with	trans-women	is	caused	both	by	moral	and	practical	reasons.		Theorists	like	John	Robertson	and	Amel	Alghrani	strongly	support	UTx	for	genetic	females	because	they	believe	that	these	women	have	the	“right	to	gestate”.		They	do	not,	however,	believe	in	trans-inclusive	UTx	because	that	“right	to	gestate”	does	not	extend	to	trans-women	and	cis-men.		UTx	for	cis-women	can	be	considered	“designed	to	restore	natural	function”	(Alghrani	638)	where	as,	in	trans-women	it	would	allow	a	fertility	function	that	was	not	naturally	intended.		These	moral	judgments	may	significantly	impact	the	future	of	trans-UTx,	but	the	most	important	factor	impeding	research	into	trans-UTx	at	this	moment	is	that	the	anatomy	of	a	male-to-female	(MTF)	patient	is	not	nearly	as	conducive	to	uterine	transplantation	as	the	anatomy	of	a	genetic	female.			In	order	for	a	MTF	trans	patient	to	receive	a	uterine	transplant,	they	would	first	need	castration	surgery	and	high	doses	of	exogenous	hormones	to	combat	their	natural	androgens	(which,	if	left	at	their	natal	levels,	could	threaten	pregnancy).		They	would	also	need	to	have	a	neovagina	created	(if	they	didn’t	already	have	one)	to	allow	for	menstruation	and	the	eventual	implantation	of	embryos	(Maron,	Transgender).		Additionally,	while	the	majority	of	genetic	females	who	lack	uteri	still	have	most,	if	not	all,	of	the	internal	structures	necessary	to	support	the	uterus,	genetic	males	lack	the	uterine	veins	and	arteries	needed	to	nurture	the	womb.		Though	it	will	be	more	difficult,	Dr.	Chung	has	proposed	attaching	a	branch	of	a	large	vessel,	like	the	internal	iliac,	to	the	donor	uterus	upon	transplantation	
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(Gordon).		If	UTx	in	genetic	females	proves	to	be	viable,	I	predict	that	research	into	trans-UTx	will	quickly	follow.		While	the	process	will	be	more	complicated,	there	is	a	vast	network	of	people	who	would	be	willing	to	undergo	uterine	transplantation	in	order	to	achieve	this	level	of	reproductive	autonomy.					At	this	moment,	while	UNOS	has	accepted	cis-gendered	uterine	transplantation,	there	is	no	way	to	know	how	trans-UTx	might	be	dealt	with	by	the	network.		Mark	Sauer,	professor	of	obstetrics	and	gynecology	at	Columbia	University,	and	a	member	of	The	American	Society	for	Reproductive	Medicine’s	Ethics	Committee,	disclosed	that	while	the	board	has	started	discussions	about	the	potential	prioritization	and	allocation	of	uterine	transplants,	trans-recipients	have	not	been	a	part	of	the	conversation	(Maron,	Transgender).		The	erasure	of	trans	individuals	from	this	discussion	may	foreshadow	uneven	allocation	trends	if	there	does	come	a	time	where	both	cis	and	trans	individuals	are	on	waiting	lists	for	donor	uteri.		It	is	not	unreasonable	to	fear	that	genetic	sex	may	one	day	constitute	a	variable	in	the	allocation	process	of	uterine	transplants,	with	genetic	females	being	afforded	a	higher	level	of	priority.		One	factor	that	would	help	trans-UTx	immensely	is	that	female-to-male	(FTM)	patients	are	often	more	than	willing	to	part	with	their	uteri.		Cecile	Unger,	a	specialist	in	female	pelvic	medicine	at	the	Cleveland	Clinic,	has	stated	that	around	one	third	of	her	female-to-male	patients	have	requested	to	donate	their	uteri	for	transplantation	(Maron,	Transgender).		At	this	point,	these	requests	are	being	denied,	but	if	there	comes	a	time	where	trans-UTx	is	in	clinical	trials	or	readily	available,	there	will	probably	be	no	shortage	of	donor	uteri	from	FTM	patients.		
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While	some	of	these	uteri	may	be	regulated	by	UNOS,	it	might	also	be	possible	to	create	a	trans-network	of	organ	sharing.		While	this	system	could	definitely	work	on	a	more	individual	level,	with	trans	men	donating	their	uteri	to	MTF	friends	or	family	members,	it	could	also	be	regulated	on	a	grander	scale	by	an	online	system	capable	of	matching	trans	recipients	with	biologically	compatible	trans	donors.		As	more	patients	seek	the	benefits	of	UTx,	the	question	of	payment	will	arise.		Even	now,	many	insurance	companies	do	not	cover	assisted	reproductive	technologies	like	IVF,	and	if	they	do,	they	often	only	cover	one	or	two	cycles.		Uterine	transplants	will	be	much	more	expensive,	as	they	have	an	estimated	cost	of	up	to	$300,000	(Hastings	Center)	and	will	require	lengthy	hospital	stays	for	both	the	donor	and	the	recipient.			It	is	unlikely	that	insurance	companies	will	be	quick	to	cover	this	procedure.		If	these	procedures	are	not	incorporated	into	insurance	packages,	uterine	transplants	are	sure	to	follow	the	same	path	as	the	more	established	ARTs—where	they	are	available	to	the	privileged	upper	class	and	remain	unreachable	by	middle	and	lower	class	individuals	who	could	greatly	benefit	from	them.		The	issue	of	payment	will	be	specifically	glaring	for	trans-patients,	as	many	trans-men	and	women	already	struggle	to	afford	hormone	treatments	and	top/bottom	surgeries.		While	certain	insurance	plans	do	cover	gender	reassignment	surgeries,	there	are	specific	qualifications	that	must	be	met	in	order	for	the	surgery	to	be	deemed	“medically	necessary”	and	all	procedures	considered	to	be	cosmetic	are	excluded	from	coverage	(HRC).		It	is	possible	that	some	providers	might	one	day	consider	UTx	to	be	a	necessary	part	of	the	reassignment	process,	but	it	is	more	likely	that	it	will	be	considered	cosmetic	and	remain	largely	unattainable.			
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One	indisputable	aspect	of	the	future	of	UTx	is	that	uterine	transplant	babies	will	be	closely	observed	over	the	next	decade.		While,	at	this	point,	researchers	believe	that	children	gestated	in	UTx	uteri	have	not	been,	and	will	not	be,	negatively	affected	by	this	form	of	gestation,	more	time	and	a	larger	sample	size	will	be	required	before	they	can	make	concrete	claims.		Caplan	has	suggested	that,	once	the	current	clinical	trials	are	finished,	the	medical	community	take	a	few	years	to	track	a	small	group	of	UTx	recipients	and	their	children.		This	way,	they	might	be	able	to	gauge	how	the	transplant	affects	the	health	and	development	of	UTx	babies	before	the	procedure	becomes	more	widely	available	(Tedeschi).		Though	this	seems	like	a	practical	tactic,	urging	from	potential	UTx	patients	coupled	with	the	desire	to	provide	this	cutting	edge	procedure	might	prompt	certain	hospitals	to	forego	the	waiting	period	and	offer	UTx	as	soon	as	possible.			If	UTx	moves	past	clinical	trails	and	becomes	a	part	of	the	American	medical	system,	reproduction	in	this	country	will	be	forever	changed.		Moreover,	if	trans-UTx	is	actualized,	or	if	bioprinting	becomes	a	viable	source	of	transplantable	uteri,	reproduction	and	gestation	will	reach	a	new	level	of	unnatural.		It	is	imperative	that	we	acknowledge	that	each	step	forward	in	UTx	takes	us	farther	away	from	the	traditional	systems	of	reproduction	and	gestation.		Whether	this	potential	departure	from	natural	gestation	is	positive	or	negative	is	not	the	focus	of	this	thesis,	but	there	will	surely	be	strong	arguments	for	both	sides	if	UTx	research	progresses.						
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Conclusion	
	Uterine	transplantation,	while	imagined	and	discussed	for	centuries,	became	corporeal	when	Lili	Elbe	went	under	the	knife	in	1931.		Decades	later,	it	seems	that	UTx	may	become	an	integral	part	of	the	future	of	assisted	reproductive	technologies.		Uterine	transplantation	has	now	been	attempted	in	three	official	human	clinical	trials	and	many	more	animal	studies	and	there	are	currently	5	children	in	Sweden	who	were	gestated	in	donor	uteri.		When	looking	at	the	path	that	this	procedure	has	followed,	it	seems	evident	to	me	that	UTx	is	on	track	to	gain	approval	in	several	countries	(including	the	US,	Sweden	and	Great	Britain).	Throughout	this	thesis	I	have	demonstrated	the	bioethical	problems	associated	with	uterine	transplantation.		I	have	also	indicated	that	it	is	a	controversial	issue;	with	certain	bioethicists	strongly	opposing	its	progression,	and	others	praising	the	procedure	for	aiding	female	procreative	liberty.		While	the	ethical	issues	associated	with	UTx	may	seem	potentially	prohibitive,	it	is	necessary	to	acknowledge	that	all	current	medical	procedures	(ranging	from	IVF	to	kidney	transplants)	are	associated	with	certain	bioethical	issues.		Therefore,	an	examination	into	the	specific	ethical	problems	and	the	counteracting	benefits	must	be	conducted	before	any	new	medical	or	scientific	technique	is	approved.		I	have	attempted	to	perform	an	abbreviated	version	of	this	assessment	for	UTx	and	have	come	to	the	conclusion	that,	while	the	progression	of	uterine	transplantation	should	be	cautious	and	highly	regulated,	it	should	continue,	due	to	the	fact	that	this	procedure	has	the	potential	to	provide	immeasurable	quality-of-life	benefits	to	individuals	who	lack	uteri.			
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While	I	don’t	think	that	UTx	will	ever	become	“common	practice”,	I	believe	it	should	be	available	for	the	specific	individuals	who,	after	being	fully	informed,	consent	to	undergo	the	procedure.		The	multiple	procedures	required	in	order	to	attain	a	uterus,	and	subsequently	gestate	a	fetus,	may	not	seem	“worth	it”	to	an	outsider,	but	it	is	impossible	to	quantify	the	desire	felt	by	these	individuals.		Since	UTx	provides	an	opportunity	that	is	not	made	available	by	any	pre-existing	medical	technology,	I	consider	it	to	pass	clinical	equipoise	and	be	justifiable.		However,	before	uterine	transplantation	graduates	from	clinical	trials	and	becomes	mainstream,	a	variety	of	regulations	will	need	to	be	nailed	down.		I	hope	to	see	the	establishment	of	strict	qualifications	for	all	potential	UTx	recipients,	outlined	procedures	for	procurement	of	uteri	from	live	and	dead	donors,	and	guidelines	for	how	to	deal	with	any	malfunctions	that	may	occur	during	the	procedure	and	the	subsequent	gestational	period.		It	will	also	be	necessary	for	UNOS	to	publish	specific	allocation	policies	regarding	uteri.		Finally,	it	will	be	interesting	to	see	the	future	of	this	procedure	in	terms	of	payment,	as	most	insurance	providers	will	probably	resist	incorporating	the	expensive	and	rare	procedure	into	their	policies.				 Uterine	transplantation	has	the	opportunity	to	change	the	face	of	human	reproduction	in	a	similar	way	to	IVF,	the	procedure	that	revolutionized	the	field	of	assisted	reproductive	technologies	in	the	late	1970s.		Transcending	the	reach	of	traditional	IVF,	UTx	might	also	allow	procreation	and	gestation	to	become	more	accessible	to	gender-bending	members	of	society,	such	as	trans-women	and	cis-men	who	desire	the	experience	of	pregnancy.		UTx,	for	the	first	time	in	history,	is	giving	individuals	who	lack	uteri	the	opportunity	to	achieve	reproductive	success	in	the	
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form	of	pregnancy	and	childbirth.		While	it	is	essential	to	acknowledge	and	mitigate	the	bioethical	issues	associated	with	UTx,	they	are	not	grave	enough	to	derail	this	progress.			 																				
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Appendix	A	Human	Uterine	Transplant	Model		
	Source:		Grady,	Denise.	"Uterus	Transplants	May	Soon	Help	Some	Infertile	Women	in	the	U.S.	Become	Pregnant."	New	York	Times.	The	New	York	Times	Company,	12	Nov.	2015.	Web.		 					 				
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Appendix	B	Excerpt	–The	Montreal	Criteria	for	the	Ethical	Feasibility	of	Uterine	Transplantation	
	1.	Criteria	for	the	Ethical	Feasibility	of	UTx	
	Source:		Lefkowitz,	Ariel,	Marcel	Edwards,	and	Jacques	Balayla.	"The	Montreal	Criteria	for	the	Ethical	Feasibility	of	Uterine	Transplantation."	Transplant	International	25.4	(2012):	444.	Web.	
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2.	Ethical	Principles	and	Uterine	Transplantation			
Source:		Lefkowitz,	Ariel,	Marcel	Edwards,	and	Jacques	Balayla.	"The	Montreal	Criteria	for	the	Ethical	Feasibility	of	Uterine	Transplantation."	Transplant	International	25.4	(2012):	445.	Web.		
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